XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.
Metrics to compare | XRTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXRTXPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.8x | −0.3x | −0.5x | |
PEG Ratio | −0.05 | 0.00 | 0.00 | |
Price/Book | 1.4x | 0.6x | 2.6x | |
Price / LTM Sales | - | 1.5x | 3.3x | |
Upside (Analyst Target) | - | 22.6% | 42.8% | |
Fair Value Upside | Unlock | 16.9% | 6.5% | Unlock |